12:00 AM
Mar 01, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TMC435: Phase II started

Medivir disclosed that in September it began a double-blind, placebo-controlled Phase II (C206) trial to evaluate Pegasys peginterferon alfa-2a and ribavirin plus TMC435 in 455 patients. J&J's Tibotec...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >